Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations
Background: We report a comprehensive overview of current Chronic Obstructive
Lung Disease (COPD) therapies and discuss the development of possible new pharmacological
approaches based on “new” knowledge. Specifically, sensitivity/resistance to corticosteroids
is evaluated with a special focus on the role of gene mutations in drug response.
Objective: Critically review the opportunities and the challenges occurring in the treatment of
Conclusion: Findings from “omics” trials should be used to learn more about biologically targeted
drugs, and to select more specific drugs matching patient’s distinctive molecular profile.
Specific markers of inflammation such as the percentage of eosinophils are important in
determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide
polymorphisms: SNPs) may influence drug sensitivity or resistance.Clinicians working in
a real-world need to have a suitable interpretation of molecular results together with a guideline
for the treatment and recommendations. Far more translational research is required before
new results from omics techniques can be applied in personalized medicine in real-world settings.
No Supplementary Data
No Article Media
Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
Unit of Clinical and Molecular Epidemiology, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy.
Unit of Pulmonary Rehabilitation, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy.
Scientific Direction, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy.
Appeared or available online: September 6, 2018